Gesta, S., Tseng, Y.-H. & Kahn, C. R. Developmental origin of fat: tracking obesity to its source. Cell 131, 242–256 (2007).

Article  CAS  PubMed  Google Scholar 

Johansen, V. B. I. et al. Brain control of energy homeostasis: implications for anti-obesity pharmacotherapy. Cell 188, 4178–4212 (2025). This article summarizes key neuroendocrine and neural circuit mechanisms underpinning current and emerging anti-obesity therapies.

Article  CAS  PubMed  Google Scholar 

Magkos, F. et al. On the pathogenesis of obesity: causal models and missing pieces of the puzzle. Nat. Metab. https://doi.org/10.1038/s42255-024-01106-8 (2024).

Article  PubMed  Google Scholar 

Rubino, F. et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 13, 221–262 (2025).

Article  PubMed  PubMed Central  Google Scholar 

GBD 2015 Obesity Collaborators. Health effects of overweight and obesity in 195 countries over 25 years. N. Engl. J. Med. 377, 13–27 (2017).

Article  Google Scholar 

NCD Risk Factor Collaboration (NCD-RisC) Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet 403, 1027–1050 (2024).

Article  Google Scholar 

World Obesity Federation. World Obesity Atlas 2025. worldobesity.org https://www.worldobesity.org/resources/resource-library/world-obesity-atlas-2025 (2025).

Rubino, F. et al. Joint international consensus statement for ending stigma of obesity. Nat. Med. 26, 485–497 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hall, K. D. & Kahan, S. Maintenance of lost weight and long-term management of obesity. Med. Clin. North Am. 102, 183–197 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Look AHEAD Research Group. Eight-year weight losses with an intensive lifestyle intervention: the look AHEAD study. Obesity 22, 5–13 (2014).

Article  Google Scholar 

Müller, T. D., Clemmensen, C., Finan, B., DiMarchi, R. D. & Tschöp, M. H. Anti-obesity therapy: from rainbow pills to polyagonists. Pharmacol. Rev. 70, 712–746 (2018).

Article  PubMed  Google Scholar 

Wilding, J. P. H. et al. Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. 384, 989–1002 (2021). This article reports landmark clinical trial evidence that supports the efficacy of semaglutide 2.4 mg for weight management in adults with overweight or obesity without T2D.

Article  CAS  PubMed  Google Scholar 

Lincoff, A. M. et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N. Engl. J. Med. 389, 2221–2232 (2023). This article shows the effect of semaglutide 2.4 mg on cardiovascular outcomes in people with overweight or obesity without T2D.

Article  CAS  PubMed  Google Scholar 

Aronne, L. J. et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2416394 (2025). This article reports the landmark trial comparing the effects of semaglutide and tirzepatide at their maximum tolerated doses in adults with obesity, or with overweight and at least one prespecified comorbidity.

Article  PubMed  Google Scholar 

Kosiborod, M. N. et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N. Engl. J. Med. 389, 1069–1084 (2023).

Article  CAS  PubMed  Google Scholar 

Perkovic, V. et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N. Engl. J. Med. 391, 109–121 (2024).

Article  CAS  PubMed  Google Scholar 

Sanyal, A. J. et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N. Engl. J. Med. 392, 2089–2099 (2025). This article reports the effects of semaglutide 2.4 mg in individuals with biopsy-confirmed MASH and stage 2 or 3 fibrosis.

Article  CAS  PubMed  Google Scholar 

Jastreboff, A. M. et al. Tirzepatide once weekly for the treatment of obesity. N. Engl. J. Med. 387, 205–216 (2022). This article demonstrates the efficacy of tirzepatide 5, 10 and 15 mg in people with overweight or obesity without T2D.

Article  CAS  PubMed  Google Scholar 

Malhotra, A. et al. Tirzepatide for the treatment of obstructive sleep apnea: rationale, design, and sample baseline characteristics of the SURMOUNT-OSA phase 3 trial. Contemp. Clin. Trials 141, 107516 (2024). This article demonstrates the efficacy of tirzepatide in people with overweight or obesity and obstructive sleep apnoea.

Article  PubMed  PubMed Central  Google Scholar 

Packer, M. et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N. Engl. J. Med. 392, 427–437 (2025).

Article  CAS  PubMed  Google Scholar 

Jastreboff, A. M. et al. Tirzepatide for obesity treatment and diabetes prevention. N. Engl. J. Med. 392, 958–971 (2025). This article reports the safety and efficacy of tirzepatide for obesity treatment and T2D prevention over 3 years of treatment in adults with obesity and prediabetes.

Article  CAS  PubMed  Google Scholar 

le Roux, C. W. et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. 12, 162–173 (2024).

Article  PubMed  Google Scholar 

Ji, L. et al. Once-weekly mazdutide in chinese adults with obesity or overweight. N. Engl. J. Med. 392, 2215–2225 (2025).

Article  CAS  PubMed  Google Scholar 

Coskun, T. et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 34, 1234–1247.e9 (2022). This article presents the discovery and preclinical characterization of retatrutide, a unimolecular GLP1R–GIPR–GCGR tri-agonist.

Article  CAS  PubMed  Google Scholar 

Kruse, T. et al. Development of cagrilintide, a long-acting amylin analogue. J. Med. Chem. 64, 11183–11194 (2021). This article describes the medicinal chemistry optimization and early preclinical evaluation of cagrilintide.

Article  CAS  PubMed  Google Scholar 

Dahl, K. et al. NN1213 - a potent, long-acting, and selective analog of human amylin. J. Med. Chem. 67, 11688–11700 (2024).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Billings, L. K. et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet 406, 2631–2643 (2025). This article demonstrates the weight loss efficacy of the selective AMLNR agonist, eloralintide, in people with obesity.

Article  CAS  PubMed  Google Scholar 

Kuhre, R. E. et al. The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats. EBioMedicine 118, 105862 (2025).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Clemmensen, C., Gerhart-Hines, Z., Schwartz, T. W., Zierath, J. R. & Sakamoto, K. Shaping the future of cardiometabolic innovation: advances and opportunities. Nat. Metab. 7, 1495–1497 (2025).

Article  PubMed  Google Scholar 

Garvey, W. T. et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am. J. Clin. Nutr. 95, 297–308 (2012).

Article  CAS  PubMed  Google Scholar 

Gadde, K. M. et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 377, 1341–1352 (2011).

Article  CAS  PubMed  Google Scholar 

Allison, D. B. et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity 20, 330–342 (2012).

Article  CAS  PubMed  Google Scholar 

Greenway, F. L. et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 376, 595–605 (2010).

Article  CAS